PASADENA, Calif.--(BUSINESS WIRE)--
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
Bruce Given, M.D., Arrowhead's chief operating officer, will present at
BioCentury's 21st Annual NewsMakers in the Biotech Industry
conference on September 26, 2014 at 10:30 a.m. EDT in New York.
Investors may access a live and archived audio webcast on the Company's
website at http://ir.arrowheadresearch.com/events.cfm.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic
hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency, and partner-based programs in obesity and
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company's email list to receive news directly, please
send an email to firstname.lastname@example.org.
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Martina Schwarzkopf, Ph.D.
Source: Arrowhead Research Corporation
News Provided by Acquire Media